Trial Profile
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs INCAGN 1949 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Biosciences International
- 03 Jan 2020 Status changed from active, no longer recruiting to completed.
- 04 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Jul 2020.
- 04 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Nov 2019.